Severe thrombocytopenia induced by tirofiban after percutaneous coronary intervention: a case report

Journal of Medical Case Reports

Case Report

Ya-Fei Li¹  Dian-Fu Li²  Ze-Mu Wang²  Qin Shen²  Lian-Sheng Wang²  Bei Chen²  Bin Wang³ 

[1] Department of Cardiology, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Gusu School, Nanjing Medical University, Suzhou, China;Department of Cardiology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China;Institute of Nephrology, Zhong Da Hospital, Southeast University School of Medicine, Nanjing, China;

关键词: Glycoprotein IIb/IIIa receptor antagonists;    Tirofiban;    Acute coronary syndromes;    Percutaneous coronary intervention;   

DOI  :  10.1186/s13256-023-04169-5

 received in 2021-10-17, accepted in 2023-09-09,  发布年份 2023

来源: Springer

【 摘 要 】

BackgroundTirofiban is a nonpeptide glycoprotein IIb/IIIa receptor antagonist used widely in patients subjected to percutaneous coronary intervention. While the usage of tirofiban sets an important clinical benefit, severe thrombocytopenia can occur with use of this agent.Case presentationA 76-year-old Chinese man was admitted with 1-month history of sudden onset of chest tightness. He was diagnosed as having subacute inferior myocardial infarction, and percutaneous coronary intervention was performed. After the procedure, patient received tirofiban at 0.15 µg/kg/minute for 4 h. A blood sample was obtained for a complete blood count; severe thrombocytopenia was reported according to routine orders at our hospital. All antiplatelet drugs including tirofiban, aspirin, and clopidogrel were immediately discontinued. The patient received platelet transfusions and was treated with immunoglobulin G. Two days later, the patient’s platelet count had increased to 75 × 109/L. There was a significant improvement after day 5, and the platelet count was 112 × 109/L. Seven days after the acute thrombocytopenia, he was discharged with normal platelet count.ConclusionsClinicians should be particularly aware of tirofiban-induced thrombocytopenia in routine practice.

【 授权许可】

CC BY   
© BioMed Central Ltd., part of Springer Nature 2023

【 图 表 】

Fig. 1

13100_2023_302_Article_IEq7.gif

Fig. 6